Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, AP-HP, University of Paris, CEDEX 14, 75679 Paris, France.
INSERM U1016, Cochin Institute, Paris, University of Paris, CNRS UMR 8104, 75014 Paris, France.
Viruses. 2021 Apr 26;13(5):758. doi: 10.3390/v13050758.
The incidence of pulmonary embolism (PE) is high during severe Coronavirus Disease 2019 (COVID-19). We aimed to identify predictive and prognostic factors of PE in non-ICU hospitalized COVID-19 patients. In the retrospective multicenter observational CLOTVID cohort, we enrolled patients with confirmed RT-PCR COVID-19 who were hospitalized in a medicine ward and also underwent a CT pulmonary angiography for a PE suspicion. Baseline data, laboratory biomarkers, treatments, and outcomes were collected. Predictive and prognostics factors of PE were identified by using logistic multivariate and by Cox regression models, respectively. A total of 174 patients were enrolled, among whom 86 (median [IQR] age of 66 years [55-77]) had post-admission PE suspicion, with 30/86 (34.9%) PE being confirmed. PE occurrence was independently associated with the lack of long-term anticoagulation or thromboprophylaxis (OR [95%CI], 72.3 [3.6-4384.8]) D-dimers ≥ 2000 ng/mL (26.3 [4.1-537.8]) and neutrophils ≥ 7.0 G/L (5.8 [1.4-29.5]). The presence of these two biomarkers was associated with a higher risk of PE ( = 0.0002) and death or ICU transfer (HR [95%CI], 12.9 [2.5-67.8], < 0.01). In hospitalized non-ICU severe COVID-19 patients with clinical PE suspicion, the lack of anticoagulation, D-dimers ≥ 2000 ng/mL, neutrophils ≥ 7.0 G/L, and these two biomarkers combined might be useful predictive markers of PE and prognosis, respectively.
新型冠状病毒病 2019(COVID-19)患者中肺栓塞(PE)的发生率较高。我们旨在确定非 ICU 住院 COVID-19 患者中 PE 的预测和预后因素。在回顾性多中心观察性 CLOTVID 队列中,我们招募了经 RT-PCR 确诊为 COVID-19 且因疑似 PE 而行 CT 肺动脉造影的住院患者。收集了基线数据、实验室生物标志物、治疗和结局。分别使用逻辑多元回归和 Cox 回归模型确定 PE 的预测和预后因素。共纳入 174 例患者,其中 86 例(中位[IQR]年龄 66 岁[55-77])有住院后疑似 PE,30/86(34.9%)PE 得到证实。PE 的发生与缺乏长期抗凝或血栓预防(OR[95%CI],72.3[3.6-4384.8])D-二聚体≥2000ng/mL(26.3[4.1-537.8])和中性粒细胞≥7.0G/L(5.8[1.4-29.5])独立相关。这两种生物标志物的存在与更高的 PE 风险相关( = 0.0002)和死亡或 ICU 转移风险(HR[95%CI],12.9[2.5-67.8], <0.01)。在有临床 PE 疑似的住院非 ICU 严重 COVID-19 患者中,缺乏抗凝、D-二聚体≥2000ng/mL、中性粒细胞≥7.0G/L 以及这两种生物标志物联合可能分别是 PE 和预后的有用预测标志物。